主页 > 医学新闻 >
【medical-news】新的多中心研究显示Masimo SET 脉冲量
Main Category: Cardiovascular / Cardiology
Also Included In: Pediatrics / Children's Health; Clinical Trials / Drug Trials
Article Date: 31 Jan 2009 - 1:00 PST
http://www.medicalnewstoday.com/articles/137370.php
Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced that a new multi-center study of 39,821 newborns was published in the January 2009 issue of the British Medical Journal (BMJ). When compared to a cohort group of 108,604 newborns in whom no pulse oximetry screening was used, the study found that the addition of Masimo SET pulse oximetry screening before discharge increased detection of Congenital Heart Disease (CHD) by 28% (from 72% to 92%). In addition, researchers noted that "no baby died from undiagnosed duct dependent circulation" in the Masimo SET group, while five babies from the cohort group died during the same period.(1)
In the study, Anne de-Wahl Granelli, M.D., of the Queen Silvia Children's Hospital in Goteborg, Sweden, and colleagues screened babies born between 2004 and 2007 at five well baby nurseries using Masimo SET pulse oximetry. A positive pulse oximetry result was defined as an oxygen saturation of <95% measured both preductally (right hand) and postductally (either foot), or a measurement difference >3% between the two measurements. The study found that the positive predictive value of pulse oximetry screening was at least seven times higher than the best-case scenario for standard neonatal physical examination alone (20.7% vs. 3.1%).
Undiagnosed CHD presents devastating long-term morbidity and mortality risks, with 10-30 percent of the babies who die from CHD remaining undiagnosed until autopsy.(2) Additionally, study authors noted that the rise in the proportion of babies who leave the hospital with undiagnosed critical CHD had multiple contributing factors, such as earlier discharge from maternity wards, the growing prevalence of babies rooming with their mothers instead of observational nurseries and reductions in pre-discharge neonatal clinical exams.
The researchers concluded that Masimo pulse oximetry screening of "all well babies in maternity units is practically feasible with a minimum use of nursing time" and that it "significantly improves" detection of duct dependent CHD. Researchers also commented that "the low false positive rate, the fact that other important pathology is unearthed by the screening and the likely reduced need for preoperative neonatal intensive care suggest that such screening will be cost effective."
The current study adds to previous research conducted by Dr. Granelli, which demonstrated that when compared to conventional pulse oximetry, only Masimo SET pulse oximetry is accurate and reliable for improving the detection of critical CHD.(3)
Masimo Executive Vice President of Medical Affairs Dr. Michael O'Reilly, stated: "Undiagnosed CHD frequently places the lives of newborns in grave danger. To ensure that these newborns are given the absolute best chance at survival, pre-discharge CHD detection and diagnosis is critical. The comprehensive population and protocol data gathered by these researchers demonstrate that the superior sensitivity and specificity of Masimo SET pulse oximetry technology is key to substantially increasing the ability to accurately diagnose CHD before newborns are discharged from the hospital."
(1) Anne de-Wahl Granelli, et al., "Impact of Pulse Oximetry Screening on the Detection of Duct Dependent Congenital Heart Disease: a Swedish Prospective Screening Study in 39,821 newborns." BMJ. 2009; 338;a3037. Available online at: http://www.bmj.com/cgi/content/full/338/jan08_2/a3037
(2) Bonnet D, Coltri A, Butera G, Fermont L, Le Bidois J, Kachaner J, et al., "Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality." Circulation 1999;99:916-8.
(3) Anne de-Wahl Granelli, et al., "Screening for Duct-dependent Congenital Heart Disease with Pulse Oximetry: A Critical Evaluation of Strategies to Maximize Sensitivity.." Acta Paediatrica. 2005; 94:1590-1596.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care--helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET(R), which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET(R) Pulse CO-Oximetry(TM), a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-16 05:11
医学,生命科学网